Long-Term Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis

被引：0

作者：

Rubin, David T. ^{[1
]}

Cree, Bruce A. C. ^{[2
]}

Wolf, Douglas C. ^{[3
]}

Alekseeva, Olga ^{[4
]}

Charles, Lorna ^{[5
]}

Petersen, AnnKatrin ^{[5
]}

Sheffield, James K. ^{[5
]}

Cheng, Chun-Yen ^{[5
]}

Riolo, Jon V. ^{[5
]}

Silva, Diego ^{[5
]}

Lublin, Fred D. ^{[6
]}

Cohen, Jeffrey A. ^{[7
]}

Danese, Silvio ^{[8
]}

机构：

[1] Univ Chicago Med, Ctr Inflammatory Bowel Dis, Chicago, IL USA

[2] Univ Calif San Francisco, Weill Inst Neurosci, San Francisco, CA USA

[3] Atlanta Gastroenterol Associates, Ctr Crohns Dis & Ulcerat Colitis, Atlanta, GA USA

[4] Nizhny Novgorod Reg Clin Hosp, Nizhnii Novgorod, Nizhegorod, Russia

[5] Bristol Myers Squibb, Princeton, NJ USA

[6] Mt Sinai Med Ctr, New York, NY USA

[7] Cleveland Clin, Mellen Ctr MS Treatment & Res, Cleveland, OH USA

[8] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Milan, Lombardia, Italy

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

S911

引用

页码：S680 / S680

页数：1

共 50 条

[31] Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
Yasuo Suzuki
Satoshi Motoya
Hiroyuki Hanai
Takayuki Matsumoto
Toshifumi Hibi
Anne M. Robinson
Nael M. Mostafa
Jingdong Chao
Vipin Arora
Anne Camez
Roopal B. Thakkar
Mamoru Watanabe
Journal of Gastroenterology, 2014, 49 : 283 - 294
[32] Integrated summary of safety of obefazimod for patients with moderately to severely active ulcerative colitis
Vermeire, S.
Peyrin-Biroulet, L.
Danese, S.
Dubinsky, M.
Dulai, P. S.
Tilg, H.
Siegmund, B.
Hisamatsu, T.
Shan, K.
Jacobstein, D.
Cataldi, F.
Rabbat, C.
Sands, B. E.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1554 - i1555
[33] Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
Suzuki, Yasuo
Motoya, Satoshi
Hanai, Hiroyuki
Matsumoto, Takayuki
Hibi, Toshifumi
Robinson, Anne M.
Mostafa, Nael M.
Chao, Jingdong
Arora, Vipin
Camez, Anne
Thakkar, Roopal B.
Watanabe, Mamoru
JOURNAL OF GASTROENTEROLOGY, 2014, 49 (02) : 283 - 294
[34] Judicious Use of Ozanimod for Ulcerative Colitis and Multiple Sclerosis
Jhon, Gabriela F.
Forster, Erin M.
ACG CASE REPORTS JOURNAL, 2024, 11 (04)
[35] LONG-TERM SAFETY OF OFATUMUMAB IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
Hauser, Stephen
Cross, Anne
Winthrop, Kevin
Wiendl, Heniz
Nicholas, Jacqueline
Meuth, Sven
Giacomini, Paul
Sacca, Francesco
Su, Wendy
Kappos, Ludwig
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09):
[36] Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis
Dulai, Parambir S.
Mosli, Mahmoud
Khanna, Reena
Levesque, Barrett G.
Sandborn, William J.
Feagan, Brian G.
PHARMACOTHERAPY, 2015, 35 (04): : 412 - 423
[37] Long-Term Safety and Efficacy of Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the PURSUIT-SC Maintenance Study Extension
Gibson, Peter R.
Reinisch, Walter
Sandborn, William
Feagan, Brian G.
Marano, Colleen W.
Strauss, Richard
Johanns, Jewel
Zhang, Hongyan
Padgett, Lakshmi
Colombel, Jean-Frederic
Collins, Judith
Rutgeerts, Paul J.
GASTROENTEROLOGY, 2014, 146 (05) : S587 - S587
[38] Long-term safety and efficacy of golimumab in patients with moderately to severely active ulcerative colitis: Results from the PURSUIT-SC Maintenance study extension
Reinisch, W.
Gibson, P.
Sandborn, W. J.
Feagan, B. G.
Marano, C.
Strauss, R.
Johanns, J.
Zhang, H.
Padgett, L.
Colombel, J. -F.
Collins, J.
Rutgeerts, P.
JOURNAL OF CROHNS & COLITIS, 2014, 8 : S6 - S7
[39] Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis
Taxonera, Carlos
Iborra, Marisa
Maia Bosca-Watts, Marta
Rubio, Saioa
Nantes, Oscar
Higuera, Rebeca
Bertoletti, Federico
Martinez-Montiel, Pilar
Sierra-Ausin, Monica
Mancenido, Noemi
Lazar Perez-Calle, Jose
Algaba, Alicia
Olivares, David
Alba, Cristina
CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (07) : 1297 - 1304
[40] Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension
Reinisch, Walter
Gibson, Peter R.
Sandborn, William J.
Feagan, Brian G.
Strauss, Richard
Johanns, Jewel
Padgett, Lakshmi
Adedokun, Omoniyi J.
Colombel, Jean-Frederic
Collins, Judith
Rutgeerts, Paul
Tarabar, Dino
Marano, Colleen
JOURNAL OF CROHNS & COLITIS, 2018, 12 (09): : 1053 - 1066

← 1 2 3 4 5 →